Patent Reform Act of 2010 | S. 515 |
3/5/2010
Leaders of the Senate Judiciary Committee have announced details of an agreement on long-pending legislation to make needed reforms to the nation’s patent system. More...
USPTO Proposed Budget for Fiscal Year 2011 | 10-07 |
2/1/2010
Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office (“USPTO”) David Kappos has announced President Barack Obama’s $2.322 billion fiscal year 2011 (FY 2011) budget request for the USPTO. More...
Preserve Access to Affordable Generics Act | S. 369 |
10/15/2009
The U.S. Senate Judiciary Committee has voted to pass a compromise version of Senator Herb Kohl’s bill banning pay-for-delay settlements that keep generic drugs off the market. More...
To Authorize the Director of the United States Patent and Trademark Office to Use Funds Made Available under the Trademark Act | S. 1358, H.R. 3114 |
7/27/2009
Both Houses of Congress have passed a bill authorizing the Director of the U.S. Patent and Trademark Office (“USPTO”) to establish a surcharge on patent fees to repay any borrowed trademark fees. More...
Drug Price Competition Act of 2009 | S. 1315 |
6/22/2009
Sen. Bill Nelson, D-Fl., has filed a proposed legislation to amend Hatch-Waxman Act's definition of “first applicant” for abbreviated new drug application (“ANDA”) filers to give generic-drug makers challenging brand-name patents an opportunity at receiving 180-day market exclusivity. More...
Protecting Consumer Access to Generic Drugs Act of 2009 | H.R. 1706 |
3/25/2009
Rep. Bobby L. Rush, D-Il., has re-introduced on the congressional floor a bill intended to eliminate perceived anticompetitive settlements of patent infringement litigation between generic and brand-name pharmaceutical manufacturers. More...
Patent Reform Act of 2009 | S. 610 |
3/17/2009
U.S. Senator Jon Kyl (R-Az) has filed his own version of Patent Reform Act of 2009 (S. 610). More...
A bill to prohibit the use of Federal funds to approve certain biologics license applications by the FDA | S. 613 |
3/17/2009
Sen. Sam Brownback, R-Kansas, has filed a billed that would prohibit the U.S. Food and Drug Administration (“FDA”) from using federal funds to process biologics license applications for products that contain certain “select agents or toxins.” More...
Patent Reform Act of 2009 | S. 515 |
4/2/2009
At a business meeting held on April 2, 2009, the Senate Judiciary Committee voted to report critical legislation to make reforms to the nation’s dated patent reform system. More...
Pathway for Biosimilars Act | H.R. 5629, H.R. 1548 |
3/17/2009
Representatives Anna G. Eshoo (D – CA), Jay Inslee (D – WA), and Joe Barton (R – TX) have introduced the “Pathway for Biosimilars Act” (H.R. 1548). The bill creates a process for approval of “biosimilars” or “follow-on biologics” while protecting patient health and safety, lowering health care costs, and providing adequate incentives for innovation.
More...